Why the study?
The study was conducted to assess the association between prehypertension and left ventricular hypertrophy (LVH) at entry, as well as the risk of new-onset LVH associated with this condition in participants with normal baseline left ventricular mass index.
Does prehypertension increase the risk of developing left ventricular hypertrophy compared to normotension?
Does prehypertension increase the risk of developing left ventricular hypertrophy compared to normotension?
Answers are grounded in this paper and cite their sources.
Prehypertension is associated with a significantly increased risk of developing left ventricular hypertrophy over 10 years, particularly when progressing to sustained hypertension.
Cross-sectional and longitudinal data analysis of the PAMELA (Pressioni Monitorate E Loro Associazioni) population was performed to assess the association between prehypertension and left ventricular hypertrophy (LVH) at entry and the risk of new-onset LVH associated to this condition in the subset of participants with normal LV mass index (LVMI). A total of untreated 1397 participants with measurable echocardiographic parameters at baseline were considered in the cross-sectional analysis. The longitudinal analysis included 880 participants without LVH at baseline and with measurable LVMI at follow-up examination performed 10 years later. At entry, after adjustment for major confounders LVH prevalence rates (LVM/body surface area) showed a significant, progressive increase from the normotensive (2.1%), to prehypertension (6.7%), and hypertension group (18.3%). The incidence of LVH increased progressively from the normotensive to prehypertension and hypertension group (9.0%, 23.2%, and 36.5%, respectively). The risk of new LVH was significantly greater in prehypertension who progressed to sustained hypertension (odds ratio, 4.21; CI, 1.64-10.83; P=0.003) than in those with persistent prehypertension (odds ratio, 1.89; CI, 0.77-5.11; P=0.21) compared with persistent normotensive participants after adjustment for age, sex, baseline LVMI, obesity, glucose, creatinine, total cholesterol and the use of antihypertensive drugs at follow-up. Further adjustments for changes in body mass index, metabolic variables, and creatinine during the follow-up did not modify the strength of association between prehypertension and new-onset LVH. Our findings offer a new piece of evidence on the association of prehypertension with LVH and support the view that preventive actions for this condition affecting a large fraction of the general population should be intensified.
No takes yet. Share an insight, caveat, or question.
Cuspidi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: